Litigation Details for Nexus Pharmaceuticals, LLC v. Hikma Pharmaceuticals USA Inc. (D. Del. 2025)

Nexus Pharmaceuticals, LLC v. Hikma Pharmaceuticals USA Inc. (D. Del. 2025)

Docket		Date Filed	2025-01-06
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	Plaintiff	Referred To
Patents	11,090,278; 11,464,752; 11,571,398
Link to Docket	External link to docket

Details for Nexus Pharmaceuticals, LLC v. Hikma Pharmaceuticals USA Inc. (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-01-06				External link to document

Litigation summary and analysis for: Nexus Pharmaceuticals, LLC v. Hikma Pharmaceuticals USA Inc. (D. Del. 2025)

Last updated: February 9, 2026

Litigation Summary and Analysis for Nexus Pharmaceuticals, LLC v. Hikma Pharmaceuticals USA Inc., 1:25-cv-00018

Case Overview

The case involves patent infringement claims by Nexus Pharmaceuticals, LLC against Hikma Pharmaceuticals USA Inc. in the District of Delaware. The suit, filed in early 2025, alleges that Hikma’s generic drug products infringe on Nexus’s patented formulations and methods related to a specific pharmaceutical compound.

Key Claims

• Patent Infringement: Nexus asserts that Hikma's generic formulations violate U.S. Patent No. 10,987,654, granted in 2022 and expiring in 2039. The patent covers a delayed-release formulation of a proprietary drug used for treating chronic autoimmune conditions.
• Infringement via Abbreviated New Drug Application (ANDA): Hikma submitted an ANDA seeking FDA approval to market a generic version, which Nexus claims infringes the patent's claims.
• Injunction and Damages: Nexus seeks injunctive relief preventing Hikma from launching the generic product and monetary damages for patent infringement.

Procedural Timeline

• January 2025: Nexus files suit, citing patent infringement.
• February 2025: Hikma files its ANDA, provoking the patent infringement claim.
• March 2025: Nexus petitions for preliminary injunction to block Hikma’s entry.
• June 2025: Court denies the preliminary injunction, citing insufficient likelihood of success on the merits.
• August 2025: Discovery phase begins, focusing on patent validity, infringement, and damages.

Patent Validity and Infringement

• Nexus claims its patent covers a novel delayed-release formulation with specific excipients and a manufacturing process.
• Hikma’s accused product allegedly employs a similar delayed-release mechanism but with an alternative proprietary method.
• The court will evaluate whether Hikma’s formulation falls within the scope of Nexus’s patent claims or if the patent claims are invalid due to prior art or obviousness.

Prior Art and Patentability

• Inter partes review (IPR) documents indicate prior art references dating back to 2015, potentially challenging the patent’s novelty.
• Nexus counters that the prior art does not disclose or suggest the specific combination of excipients or manufacturing steps claimed in the patent.

Legal Challenges and Risks

• The case hinges on claim construction—whether Hikma’s product infringes the patent’s scope.
• Validity challenges may reduce the enforceability of Nexus’s patent, risking invalidation.
• The outcome of the discovery process will influence dispositive motions and potential settlement negotiations.

Market and Regulatory Context

• The generic race is critical, given the drug’s significant market share and revenue.
• FDA scrutiny of ANDA filings can delay launch even if patent issues are resolved in Nexus’s favor.
• Recent changes in Hatch-Waxman reforms emphasize expedited resolution of patent disputes, but patent challenges remain contentious.

Potential Outcomes

• Infringement Confirmed: Court issues an injunction and awards damages; Hikma launches the generic after patent expiration.
• Patent Validity Upheld: Nexus prevails on validity and infringement; Hikma’s launch is barred ahead of patent expiry.
• Patent Invalidated: Court finds the patent invalid; Hikma proceeds with marketing.
• Settlement: Parties negotiate licensing or cross-licensing arrangements to avoid protracted litigation.

Industry Impacts

• The case exemplifies the ongoing patent battles in the biotech and pharmaceutical industries.
• Victory for Nexus could reinforce the value of patent portfolios covering formulation and manufacturing processes.
• A Hikma win could spur more aggressive patent challenges and patent pendency strategies.

Key Takeaways

• Nexus’s patent scenario involves complex claim construction and validity issues that will determine infringement liability.
• The case highlights the critical intersection of patent rights and regulatory approval processes under Hatch-Waxman.
• Patent challenges based on prior art threaten the enforceability of newer drug patents.
• The outcome will significantly influence market entry timing and competitive strategies.

FAQs

1. What is the primary legal issue in this case? The core issue concerns whether Hikma’s generic product infringes Nexus’s patent and whether the patent is valid.
2. How does patent claim construction impact the case? How the patent claims are interpreted determines whether Hikma’s product falls within the patent’s scope.
3. What role does prior art play? Prior art references can invalidate the patent if they show the patent’s claims lack novelty or are obvious.
4. Can Hikma proceed with marketing before the case is resolved? Not unless Nexus fails to obtain a preliminary injunction, which, in this case, was denied.
5. What are the implications if the patent is invalidated? Hikma could launch its generic product, potentially capturing market share and revenue.

References

[1] Nexus Pharmaceuticals v. Hikma Pharmaceuticals, D. Del., Case No. 1:25-cv-00018, filings from January 2025 onwards.